Table 3.
Multivariable analysis of the effect of concomitant immune mediated diseases on patients with inflammatory bowel diseases
| Adjusted Odds Ratio (95% CI) |
p-value | |
|---|---|---|
| All IBD, n=2,041† | ||
| Surgery | 1.26 (0.99–1.61) | 0.064 |
| Immunomodulator use | 1.11 (0.89–1.38) | 0.373 |
| Anti-TNF use | 1.31 (1.05–1.63) | 0.016 |
| Crohn’s disease, n=1,020‖ | ||
| Surgery | 1.22 (0.86–1.71) | 0.262 |
| Immunomodulator use | 0.97 (0.70–1.34) | 0.844 |
| Anti-TNF use | 1.30 (0.96–1.78) | 0.092 |
| Ulcerative Colitis, n=759¶ | ||
| Surgery | 1.36 (0.81–2.27) | 0.245 |
| Immunomodulator use | 1.22 (0.85–1.76) | 0.288 |
| Anti-TNF use | 1.43 (0.97–2.10) | 0.072 |
†
- Adjusted for disease duration, age at diagnosis, gender, smoking status and type of IBD
‖
- Adjusted for age at diagnosis, disease duration, disease location, phenotype, gender, and smoking status
¶
- Adjusted for age at diagnosis, disease duration, gender, extent of disease, and smoking status